← Eichor
Study identifier: NCT06949774 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

INcentives and ReMINDers to Improve Long-term Medication Adherence (INMIND)

Condition: HIV/AIDS · Medication Adherence · Habits  ·  Sponsor: RAND

PhaseNA
Planned participants550
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Low medication adherence when initiating antiretroviral treatment (ART) is a key barrier to HIV virologic suppression, resulting in avoidable cases of drug resistance, death, and viral transmission. Routinized pill-taking can lead to successful long-term ART adherence, and short-term behavioral economics-based supports are a novel way to overcome the limited success of existing routinization interventions. This study proposes to test this combined approach for promoting long-term ART adherence using a Stage III Sequential, Multiple Assignment, Randomized Trial (SMART) design in one of the largest HIV clinics in Uganda to identify the most cost-effective adaptive intervention that if found effective is generalizable to other settings and other chronic diseases.

This description comes directly from the study's public registry record.

Talk to the study team

Yvonne Karamagi Site Principal Investigator  ·  +256312210200  ·  yvonne.karamagi@mildmay.or.ug

Lillian Lukuse  ·  lillianlunkuse@gmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

Mildmay UgandaKampala, UgandaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06949774